Literature DB >> 10924500

Trimer carboxyl propeptide of collagen I produced by mature osteoblasts is chemotactic for endothelial cells.

D Palmieri1, L Camardella, V Ulivi, G Guasco, P Manduca.   

Abstract

During the second phase of osteogenesis in vitro, rat osteoblasts secrete inducer(s) of chemotaxis and chemoinvasion of endothelial and tumor cells. We report here the characterization and purification from mature osteoblast conditioned medium of the agent chemotactic for endothelial cells. The chemoactive conditioned medium specifically induces directional migration of endothelial cells, not affecting the expression and activation of gelatinases, cell proliferation, and scattering. Directional migration induced in endothelial cells by conditioned medium from osteoblasts is inhibited by pertussis toxin, by blocking antibodies to integrins alpha(1), beta(1), and beta(3), and by antibodies to metalloproteinase 2 and 9. The biologically active purified protein has two sequences, coincident with the amino-terminal amino acids, respectively, of the alpha(1) and of the alpha(2) carboxyl propeptides of type I collagen, as physiologically produced by procollagen C proteinase. Antibodies to type I collagen and to the carboxyl terminus of alpha(1) or alpha(2) chains inhibit chemotaxis. The chemoattractant is the propeptide trimer carboxyl-terminal to type I collagen, and its activity is lost upon reduction. These data illustrate a previously unknown function for the carboxyl-terminal trimer, possibly relevant in promoting endothelial cell migration and vascularization of tissues producing collagen type I.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924500     DOI: 10.1074/jbc.M002698200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

Review 2.  Diverse biological functions of extracellular collagen processing enzymes.

Authors:  Philip C Trackman
Journal:  J Cell Biochem       Date:  2005-12-01       Impact factor: 4.429

3.  The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function.

Authors:  Anush Oganesian; Sandra Au; Jeremy A Horst; Lars C Holzhausen; Athena J Macy; James M Pace; Paul Bornstein
Journal:  J Biol Chem       Date:  2006-10-03       Impact factor: 5.157

Review 4.  Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis.

Authors:  Ana C Martins Cavaco; Sara Dâmaso; Sandra Casimiro; Luís Costa
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

5.  Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis.

Authors:  Joseph L Sottnik; Stephanie Daignault-Newton; Xiaotun Zhang; Colm Morrissey; Maha H Hussain; Evan T Keller; Christopher L Hall
Journal:  Clin Exp Metastasis       Date:  2012-12-15       Impact factor: 5.150

6.  Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

Authors:  Christopher L Hall; Cara W Dubyk; Tracy A Riesenberger; Daniel Shein; Evan T Keller; Kenneth L van Golen
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Chondroitin sulfate proteoglycans from salmon nasal cartilage inhibit angiogenesis.

Authors:  Takashi Kobayashi; Ikuko Kakizaki; Hiroyuki Nozaka; Toshiya Nakamura
Journal:  Biochem Biophys Rep       Date:  2016-11-18

8.  The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts.

Authors:  Davide Visigalli; Daniela Palmieri; Antonella Strangio; Simonetta Astigiano; Ottavia Barbieri; Gianluigi Casartelli; Antonio Zicca; Paola Manduca
Journal:  BMC Cancer       Date:  2009-02-18       Impact factor: 4.430

9.  Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma.

Authors:  Sabina Sangaletti; Antonella Stoppacciaro; Cristiana Guiducci; Maria Rosaria Torrisi; Mario P Colombo
Journal:  J Exp Med       Date:  2003-11-10       Impact factor: 14.307

Review 10.  Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?

Authors:  Marzena Wyganowska-Świątkowska; Maja Matthews-Kozanecka; Teresa Matthews-Brzozowska; Ewa Skrzypczak-Jankun; Jerzy Jankun
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.